Literature DB >> 19204771

The efficacy of phlebotomy in a patient with prior pure red cell aplasia and iron overload secondary to transfusions.

Massimo Franchini1, Giuseppe Aprili, Gian Carlo Falezza.   

Abstract

Entities:  

Year:  2007        PMID： 19204771      PMCID： PMC2535892          DOI： 10.2450/2007.0014-07

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  8 in total

1.  ACQUIRED PURE RED CELL AGENESIS. REPORT OF 16 CASES AND REVIEW OF THE LITERATURE.

Authors:  J R SCHMID; J M KIELY; G L PEASE; M M HARGRAVES
Journal:  Acta Haematol       Date:  1963-11       Impact factor: 2.195

Review 2.  Recent acquisitions in the management of iron overload.

Authors:  Massimo Franchini
Journal:  Ann Hematol       Date:  2005-07-16       Impact factor: 3.673

3.  Hematologic and cytogenetic remission of 5q-refractory anemia after syngeneic bone marrow transplantation.

Authors:  R K Stuart; K F Mangan
Journal:  Am J Med       Date:  1986-03       Impact factor: 4.965

4.  Pure red-cell anaemia with pro-erythroblast maturation arrest.

Authors:  L Wranne; J O Bonnevier; A Killander; J Killander
Journal:  Scand J Haematol       Date:  1970

5.  Transient erythroblastopenia in infancy and childhood.

Authors:  L Wranne
Journal:  Scand J Haematol       Date:  1970

6.  Primary acquired red cell aplasia in the adult.

Authors:  J DiGiacomo; S W Furst; D D Nixon
Journal:  J Mt Sinai Hosp N Y       Date:  1966 Sep-Oct

7.  Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients.

Authors:  D A Clark; E N Dessypris; S B Krantz
Journal:  Blood       Date:  1984-02       Impact factor: 22.113

8.  Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia.

Authors:  Massimo Franchini; Giorgio Gandini; Dino Veneri; Giovanna de Matteis; Francesca Federici; Pietro Solero; Giuseppe Aprili
Journal:  Transfusion       Date:  2004-06       Impact factor: 3.157
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.